Fraxinol attenuates LPS-induced acute lung injury by equilibrating ACE-Ang II-AT1R and ACE2-Ang (1-7)-Mas and inhibiting NLRP3

Yan Wu, Xin Yang, Yuanyuan Ju, Fei ZhaoPharmaceutical 2022 · DOI

TL;DR

This study investigates the therapeutic potential of fraxinol, a natural coumarin compound, for acute lung injury (ALI). Researchers found that fraxinol effectively reduces lung inflammation and damage in mice by modulating the renin-angiotensin system (RAS) and inhibiting the NLRP3 inflammasome, suggesting it could be a promising candidate for ALI treatment.

What Problem Does This Paper Address?

Acute lung injury (ALI) is a severe and often fatal pulmonary disorder characterized by inflammation, edema, and impaired gas exchange. Despite its significance, effective treatments for ALI remain limited, leading to high morbidity and mortality rates. Lipopolysaccharide (LPS) is a common inducer of ALI in animal models, mimicking key pathological features observed in humans. The renin-angiotensin system (RAS), particularly the ACE-Ang II-AT1R axis, is known to exacerbate ALI, while the counter-regulatory ACE2-Ang (1-7)-Mas axis offers protective effects. Additionally, the NLRP3 inflammasome has emerged as a critical mediator of inflammatory responses in ALI. This paper addresses the need for novel therapeutic strategies for ALI by exploring the potential of fraxinol, a simple coumarin compound, and elucidating its underlying mechanisms of action, focusing on its interaction with the RAS and NLRP3 inflammasome.

Methods

The study employed a multi-faceted approach combining in vivo and in vitro experiments.

  • Animal Model: Male BALB/c mice were used to establish an LPS-induced ALI model. Mice were treated with varying doses of fraxinol (20, 40, and 80 mg/kg) via intraperitoneal injection after LPS administration. Control groups received PBS or LPS alone.
  • Histopathology: Lung tissues were analyzed using Hematoxylin and Eosin (H&E) staining to assess histological damage and inflammation. A lung injury scoring system was used for quantitative evaluation.
  • Pulmonary Edema Assessment: The lung wet/dry (W/D) ratio was measured to quantify fluid accumulation in the lung tissue.
  • Apoptosis Detection: TUNEL assay was performed on lung tissue sections to detect apoptotic cells.
  • Inflammation Markers: Myeloperoxidase (MPO) activity, a marker of neutrophil infiltration, was measured. Levels of pro-inflammatory cytokines TNF-α and IL-1β in bronchoalveolar lavage fluid (BALF) were quantified using ELISA.
  • Protein Expression Analysis: Western blot assays were used to measure the protein levels of key components of the RAS (ACE, AT1R, ACE2, MasR) and the NLRP3 inflammasome pathway (NLRP3, ASC, pro-caspase-1, cleaved caspase-1) in lung tissues and Raw264.7 cells.
  • Cell Culture Model: The murine macrophage cell line Raw264.7 was used to mimic ALI in vitro. Cells were treated with LPS and then with different concentrations of fraxinol.
  • Flow Cytometry: Apoptosis in Raw264.7 cells was assessed using Annexin V-PE staining and flow cytometry.
  • RAS Pathway Modulation: Specific inhibitors of the ACE2-Ang (1-7)-Mas axis (MLN-4760 for ACE2 and A779 for MasR) were used in cell culture experiments to investigate the role of this pathway.
  • NLRP3 Activation: Nigericin, an NLRP3 inflammasome agonist, was used in cell culture to further explore the role of NLRP3.
  • Network Pharmacology: Initial predictions of potential therapeutic targets and pathways for fraxinol in ALI were made using databases like TCMSP, CTD, Malacards, Disgenet, and Swiss Target Prediction.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Fraxinol as a Dual Regulator of RAS: The study highlights fraxinol's ability to not only downregulate the pro-inflammatory ACE-Ang II-AT1R axis but also upregulate the protective ACE2-Ang (1-7)-Mas axis. This dual action suggests a sophisticated mechanism for rebalancing the RAS in ALI.
  • NLRP3 Inhibition as a Key Mechanism: Fraxinol's potent inhibition of NLRP3 inflammasome activation, evidenced by reduced NLRP3, ASC, and cleaved caspase-1 expression, is a central finding. This points to a direct anti-inflammatory effect by blocking a major inflammatory signaling cascade.
  • Synergistic Protection: The findings suggest that fraxinol's protective effects against LPS-induced ALI are likely a result of the combined actions of RAS modulation and NLRP3 inflammasome inhibition.
  • Natural Product Potential: The identification of fraxinol, a simple coumarin, as a promising therapeutic agent underscores the value of exploring natural compounds for drug discovery in complex diseases like ALI.

Key Results

  • Fraxinol significantly attenuated LPS-induced lung injury in mice, as indicated by reduced lung injury scores and pulmonary edema (lower W/D ratio).
  • Fraxinol treatment significantly reduced the number of apoptotic cells in lung tissue and Raw264.7 cells.
  • Fraxinol decreased MPO activity and lowered the levels of pro-inflammatory cytokines TNF-α and IL-1β in BALF.
  • In vivo, fraxinol treatment increased ACE2 and Ang (1-7) levels while decreasing ACE, Ang II, and AT1R levels in LPS-induced ALI mice.
  • Fraxinol significantly inhibited the expression of NLRP3, ASC, and cleaved caspase-1, while increasing pro-caspase-1 in LPS-treated mice and cells.
  • In vitro, fraxinol reduced TNF-α and IL-1β production and apoptosis in LPS-treated Raw264.7 cells.
  • Inhibition of the ACE2-Ang (1-7)-Mas axis with MLN-4760 or A779 reversed the protective effects of fraxinol on cytokine production and apoptosis, and also increased NLRP3 activation.

Limitations and Future Work

  • Inhibitor Specificity: While MLN-4760 and A779 were used to probe the ACE2-Ang (1-7)-Mas axis, the paper acknowledges that these are inhibitors and their use in cell models might not fully replicate the complex in vivo interactions.
  • Mechanism of Fraxinol Action: The precise molecular targets and pathways through which fraxinol interacts with the RAS and NLRP3 inflammasome require further detailed investigation.
  • Clinical Translation: The study was conducted in animal models and cell lines. Further research, including preclinical and clinical trials, is necessary to determine the efficacy and safety of fraxinol in human ALI patients.
  • Dosage Optimization: While effective doses were identified, further optimization for therapeutic benefit and minimizing potential side effects would be beneficial.
  • Long-term Effects: The study focused on acute effects. Investigating the long-term impact of fraxinol treatment on ALI recovery and potential chronic sequelae would be valuable.

Summary updated

Abstract

The anti-ALI effects of fraxinol maybe by equilibrating ACE-Ang II-AT1R and ACE2-Ang (1-7)-Mas axis and inhibiting NLRP3 inflammasome. Our research provides a candidate drug in the treatment of ALI.
BibTeX
@inproceedings{wu2022fraxinol,
  author = {Yan Wu and Xin Yang and Yuanyuan Ju and Fei Zhao},
  title = {{Fraxinol attenuates LPS-induced acute lung injury by equilibrating ACE-Ang II-AT1R and ACE2-Ang (1-7)-Mas and inhibiting NLRP3}},
  booktitle = {Pharmaceutical},
  year = {2022},
  doi = {10.1080/13880209.2022.2067571},
}
Figure